Weikang Pharmaceutical: The Yinhuang inhalation solution jointly developed by the company and Beijing Yingke Rui is a 2.1 category of improved traditional Chinese medicine. Post date April 29, 2022 — 11:08 Post Lock Read More Just announced a new round of Ebola outbreak! The leader of the two subdivided tracks exploded, and King Ning made an unexpected move! 16 times super bull stocks are also in trouble, how will the market go? -Stock Channel-Hexun.com Post date April 25, 2022 — 06:55 Post Lock Read More Just announced a new round of Ebola outbreak! The leader of the two sub-tracks exploded, and King Ning made an unexpected move! 16 times super bull stocks are also in trouble, how will the market go? Stocks Financial World Post date April 25, 2022 — 00:25 Post Lock Read More Weikang Pharmaceutical: In 2022, the company will continue to deepen the pharmaceutical health industry and actively cultivate various businesses in line with the development strategy. Post date April 21, 2022 — 14:29 Post Lock Read More Weikang Pharmaceutical: In 2022, the company will continue to deepen the pharmaceutical and health industry and actively cultivate various businesses in line with the development strategy_ Oriental Fortune Net Post date April 21, 2022 — 14:29 Post Lock Read More Weikang Pharmaceutical: In 2022, the company will continue to deepen the development of the pharmaceutical and health industry, and actively cultivate various businesses in line with the development strategy. Post date April 21, 2022 — 14:25 Post Lock Read More New red blood cell blood group system KANNO and human Ruan virus disease (Part 2)__Chinese Medical Post date April 11, 2022 — 17:30 Post Lock Read More Weikang Pharmaceutical: The company plans to continue to carry out pharmacodynamic research on the new coronavirus pneumonia, and plans to submit a clinical trial license application to the Center for Drug Evaluation (CDE) of the State Drug Administration by the end of 2022 Post date April 8, 2022 — 11:44 Post Lock Read More Weikang Pharmaceutical: Yinhuang inhalation solution jointly developed by the company and Beijing Yingke Rui is a 2.1 category of improved Chinese medicine_ Oriental Fortune Net Post date April 8, 2022 — 11:36 Post Lock Read More
Just announced a new round of Ebola outbreak! The leader of the two subdivided tracks exploded, and King Ning made an unexpected move! 16 times super bull stocks are also in trouble, how will the market go? -Stock Channel-Hexun.com Post date April 25, 2022 — 06:55 Post Lock Read More Just announced a new round of Ebola outbreak! The leader of the two sub-tracks exploded, and King Ning made an unexpected move! 16 times super bull stocks are also in trouble, how will the market go? Stocks Financial World Post date April 25, 2022 — 00:25 Post Lock Read More Weikang Pharmaceutical: In 2022, the company will continue to deepen the pharmaceutical health industry and actively cultivate various businesses in line with the development strategy. Post date April 21, 2022 — 14:29 Post Lock Read More Weikang Pharmaceutical: In 2022, the company will continue to deepen the pharmaceutical and health industry and actively cultivate various businesses in line with the development strategy_ Oriental Fortune Net Post date April 21, 2022 — 14:29 Post Lock Read More Weikang Pharmaceutical: In 2022, the company will continue to deepen the development of the pharmaceutical and health industry, and actively cultivate various businesses in line with the development strategy. Post date April 21, 2022 — 14:25 Post Lock Read More New red blood cell blood group system KANNO and human Ruan virus disease (Part 2)__Chinese Medical Post date April 11, 2022 — 17:30 Post Lock Read More Weikang Pharmaceutical: The company plans to continue to carry out pharmacodynamic research on the new coronavirus pneumonia, and plans to submit a clinical trial license application to the Center for Drug Evaluation (CDE) of the State Drug Administration by the end of 2022 Post date April 8, 2022 — 11:44 Post Lock Read More Weikang Pharmaceutical: Yinhuang inhalation solution jointly developed by the company and Beijing Yingke Rui is a 2.1 category of improved Chinese medicine_ Oriental Fortune Net Post date April 8, 2022 — 11:36 Post Lock Read More
Just announced a new round of Ebola outbreak! The leader of the two sub-tracks exploded, and King Ning made an unexpected move! 16 times super bull stocks are also in trouble, how will the market go? Stocks Financial World Post date April 25, 2022 — 00:25 Post Lock Read More Weikang Pharmaceutical: In 2022, the company will continue to deepen the pharmaceutical health industry and actively cultivate various businesses in line with the development strategy. Post date April 21, 2022 — 14:29 Post Lock Read More Weikang Pharmaceutical: In 2022, the company will continue to deepen the pharmaceutical and health industry and actively cultivate various businesses in line with the development strategy_ Oriental Fortune Net Post date April 21, 2022 — 14:29 Post Lock Read More Weikang Pharmaceutical: In 2022, the company will continue to deepen the development of the pharmaceutical and health industry, and actively cultivate various businesses in line with the development strategy. Post date April 21, 2022 — 14:25 Post Lock Read More New red blood cell blood group system KANNO and human Ruan virus disease (Part 2)__Chinese Medical Post date April 11, 2022 — 17:30 Post Lock Read More Weikang Pharmaceutical: The company plans to continue to carry out pharmacodynamic research on the new coronavirus pneumonia, and plans to submit a clinical trial license application to the Center for Drug Evaluation (CDE) of the State Drug Administration by the end of 2022 Post date April 8, 2022 — 11:44 Post Lock Read More Weikang Pharmaceutical: Yinhuang inhalation solution jointly developed by the company and Beijing Yingke Rui is a 2.1 category of improved Chinese medicine_ Oriental Fortune Net Post date April 8, 2022 — 11:36 Post Lock Read More
Weikang Pharmaceutical: In 2022, the company will continue to deepen the pharmaceutical health industry and actively cultivate various businesses in line with the development strategy. Post date April 21, 2022 — 14:29 Post Lock Read More Weikang Pharmaceutical: In 2022, the company will continue to deepen the pharmaceutical and health industry and actively cultivate various businesses in line with the development strategy_ Oriental Fortune Net Post date April 21, 2022 — 14:29 Post Lock Read More Weikang Pharmaceutical: In 2022, the company will continue to deepen the development of the pharmaceutical and health industry, and actively cultivate various businesses in line with the development strategy. Post date April 21, 2022 — 14:25 Post Lock Read More New red blood cell blood group system KANNO and human Ruan virus disease (Part 2)__Chinese Medical Post date April 11, 2022 — 17:30 Post Lock Read More Weikang Pharmaceutical: The company plans to continue to carry out pharmacodynamic research on the new coronavirus pneumonia, and plans to submit a clinical trial license application to the Center for Drug Evaluation (CDE) of the State Drug Administration by the end of 2022 Post date April 8, 2022 — 11:44 Post Lock Read More Weikang Pharmaceutical: Yinhuang inhalation solution jointly developed by the company and Beijing Yingke Rui is a 2.1 category of improved Chinese medicine_ Oriental Fortune Net Post date April 8, 2022 — 11:36 Post Lock Read More
Weikang Pharmaceutical: In 2022, the company will continue to deepen the pharmaceutical and health industry and actively cultivate various businesses in line with the development strategy_ Oriental Fortune Net Post date April 21, 2022 — 14:29 Post Lock Read More Weikang Pharmaceutical: In 2022, the company will continue to deepen the development of the pharmaceutical and health industry, and actively cultivate various businesses in line with the development strategy. Post date April 21, 2022 — 14:25 Post Lock Read More New red blood cell blood group system KANNO and human Ruan virus disease (Part 2)__Chinese Medical Post date April 11, 2022 — 17:30 Post Lock Read More Weikang Pharmaceutical: The company plans to continue to carry out pharmacodynamic research on the new coronavirus pneumonia, and plans to submit a clinical trial license application to the Center for Drug Evaluation (CDE) of the State Drug Administration by the end of 2022 Post date April 8, 2022 — 11:44 Post Lock Read More Weikang Pharmaceutical: Yinhuang inhalation solution jointly developed by the company and Beijing Yingke Rui is a 2.1 category of improved Chinese medicine_ Oriental Fortune Net Post date April 8, 2022 — 11:36 Post Lock Read More
Weikang Pharmaceutical: In 2022, the company will continue to deepen the development of the pharmaceutical and health industry, and actively cultivate various businesses in line with the development strategy. Post date April 21, 2022 — 14:25 Post Lock Read More New red blood cell blood group system KANNO and human Ruan virus disease (Part 2)__Chinese Medical Post date April 11, 2022 — 17:30 Post Lock Read More Weikang Pharmaceutical: The company plans to continue to carry out pharmacodynamic research on the new coronavirus pneumonia, and plans to submit a clinical trial license application to the Center for Drug Evaluation (CDE) of the State Drug Administration by the end of 2022 Post date April 8, 2022 — 11:44 Post Lock Read More Weikang Pharmaceutical: Yinhuang inhalation solution jointly developed by the company and Beijing Yingke Rui is a 2.1 category of improved Chinese medicine_ Oriental Fortune Net Post date April 8, 2022 — 11:36 Post Lock Read More
New red blood cell blood group system KANNO and human Ruan virus disease (Part 2)__Chinese Medical Post date April 11, 2022 — 17:30 Post Lock Read More Weikang Pharmaceutical: The company plans to continue to carry out pharmacodynamic research on the new coronavirus pneumonia, and plans to submit a clinical trial license application to the Center for Drug Evaluation (CDE) of the State Drug Administration by the end of 2022 Post date April 8, 2022 — 11:44 Post Lock Read More Weikang Pharmaceutical: Yinhuang inhalation solution jointly developed by the company and Beijing Yingke Rui is a 2.1 category of improved Chinese medicine_ Oriental Fortune Net Post date April 8, 2022 — 11:36 Post Lock Read More
Weikang Pharmaceutical: The company plans to continue to carry out pharmacodynamic research on the new coronavirus pneumonia, and plans to submit a clinical trial license application to the Center for Drug Evaluation (CDE) of the State Drug Administration by the end of 2022 Post date April 8, 2022 — 11:44 Post Lock Read More Weikang Pharmaceutical: Yinhuang inhalation solution jointly developed by the company and Beijing Yingke Rui is a 2.1 category of improved Chinese medicine_ Oriental Fortune Net Post date April 8, 2022 — 11:36 Post Lock Read More
Weikang Pharmaceutical: Yinhuang inhalation solution jointly developed by the company and Beijing Yingke Rui is a 2.1 category of improved Chinese medicine_ Oriental Fortune Net Post date April 8, 2022 — 11:36 Post Lock Read More
Caishen.CoCaishen.Co